BRPI0713334A8 - suspensões aquosas de tmc278 - Google Patents
suspensões aquosas de tmc278Info
- Publication number
- BRPI0713334A8 BRPI0713334A8 BRPI0713334A BRPI0713334A BRPI0713334A8 BR PI0713334 A8 BRPI0713334 A8 BR PI0713334A8 BR PI0713334 A BRPI0713334 A BR PI0713334A BR PI0713334 A BRPI0713334 A BR PI0713334A BR PI0713334 A8 BRPI0713334 A8 BR PI0713334A8
- Authority
- BR
- Brazil
- Prior art keywords
- tmc278
- aqueous suspensions
- pharmaceutical compositions
- prophylaxis
- nanoparticles
- Prior art date
Links
- 239000007900 aqueous suspension Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
suspensões aquosas de tmc278. a presente invenção refere-se a composições farmacêuticas para administração via injeção intramuscular ou subcutânea, compreendendo micro ou nanopartículas do composto tmc278 de nnrti, suspensas em um veículo aquoso farmaceuticamente aceitável, e a uso de tais composições farmacêuticas no tratamento e profilaxia de infecção por hiv.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122020011487-8A BR122020011487B1 (pt) | 2006-06-23 | 2007-06-22 | Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06115938 | 2006-06-23 | ||
EP06115938.0 | 2006-06-23 | ||
PCT/EP2007/056230 WO2007147882A2 (en) | 2006-06-23 | 2007-06-22 | Aqueous suspensions of tmc278 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0713334A2 BRPI0713334A2 (pt) | 2012-03-06 |
BRPI0713334A8 true BRPI0713334A8 (pt) | 2018-01-02 |
BRPI0713334B1 BRPI0713334B1 (pt) | 2024-02-20 |
Family
ID=38833797
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020011487-8A BR122020011487B1 (pt) | 2006-06-23 | 2007-06-22 | Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação |
BRPI0713334-0A BRPI0713334B1 (pt) | 2006-06-23 | 2007-06-22 | Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020011487-8A BR122020011487B1 (pt) | 2006-06-23 | 2007-06-22 | Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação |
Country Status (32)
Country | Link |
---|---|
US (4) | US20090176813A1 (pt) |
EP (2) | EP3366278A1 (pt) |
JP (1) | JP5292288B2 (pt) |
KR (1) | KR101406879B1 (pt) |
CN (1) | CN101478950B (pt) |
AP (1) | AP2618A (pt) |
AR (1) | AR061620A1 (pt) |
AU (1) | AU2007262941B2 (pt) |
BR (2) | BR122020011487B1 (pt) |
CA (1) | CA2654115C (pt) |
CL (1) | CL2007001847A1 (pt) |
CY (1) | CY1120564T1 (pt) |
DK (1) | DK2040671T3 (pt) |
EA (1) | EA021700B1 (pt) |
ES (1) | ES2662068T3 (pt) |
HR (1) | HRP20180629T1 (pt) |
HU (1) | HUE038797T2 (pt) |
IL (1) | IL195491A (pt) |
JO (1) | JOP20200160A1 (pt) |
LT (1) | LT2040671T (pt) |
MX (1) | MX2009000158A (pt) |
NZ (1) | NZ573291A (pt) |
PE (1) | PE20080210A1 (pt) |
PL (1) | PL2040671T3 (pt) |
PT (1) | PT2040671T (pt) |
RS (1) | RS57111B1 (pt) |
SG (1) | SG173315A1 (pt) |
SI (1) | SI2040671T1 (pt) |
TW (1) | TWI413521B (pt) |
UA (1) | UA97641C2 (pt) |
UY (1) | UY30431A1 (pt) |
WO (1) | WO2007147882A2 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
WO2010006697A2 (en) * | 2008-06-30 | 2010-01-21 | Tibotec Pharmaceuticals | Powders for reconstitution |
SG196774A1 (en) * | 2008-12-24 | 2014-02-13 | Tibotec Pharm Ltd | Implantable devices for treating hiv |
CA2832410C (en) * | 2011-04-15 | 2019-07-23 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
WO2014093941A1 (en) | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Pharmaceutical compositions |
CN106999425A (zh) * | 2014-09-26 | 2017-08-01 | 葛兰素史克知识产权第二有限公司 | 长效药物组合物 |
EP3463374A4 (en) * | 2016-05-31 | 2020-01-22 | Taimed Biologics, Inc. | PROLONGED-ACTION PHARMACEUTICAL COMPOSITION BASED ON A PROTEASE INHIBITOR |
US10369129B2 (en) * | 2016-05-31 | 2019-08-06 | Taimed Biologics, Inc. | Long acting pharmaceutical composition of protease inhibitor |
TWI678203B (zh) * | 2016-05-31 | 2019-12-01 | 中裕新藥股份有限公司 | 蛋白酶抑制劑之長效醫藥組合物 |
EP4248947A3 (en) | 2016-10-24 | 2023-11-22 | Janssen Sciences Ireland Unlimited Company | Dispersible compositions |
SI3651736T1 (sl) * | 2017-07-14 | 2021-11-30 | Janssen Pharmaceutica Nv | Formulacije z dolgim delovanjem |
CN113440529B (zh) * | 2020-03-25 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
WO2022008643A1 (en) | 2020-07-09 | 2022-01-13 | Janssen Pharmaceutica Nv | Long-acting formulations |
CA3184868A1 (en) | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
CA3182854A1 (en) | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
KR20230110763A (ko) * | 2020-11-17 | 2023-07-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 질환 또는 장애의 치료 또는 예방 |
WO2022109555A1 (en) | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
TW202333725A (zh) | 2021-11-17 | 2023-09-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 溶出測試 |
TW202408516A (zh) | 2022-04-22 | 2024-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 液體組成物 |
WO2023203255A1 (en) | 2022-04-22 | 2023-10-26 | Janssen Sciences Ireland Unlimited Company | Freeze dried compositions |
TW202408527A (zh) | 2022-05-17 | 2024-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 治療或預防hiv感染(二) |
WO2023222754A1 (en) | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Rilpivirine for use in the treatment or prevention of hiv infection |
WO2024068699A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4102124A (en) * | 1976-07-12 | 1978-07-25 | Swager William E | Locking clevis or the like |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5046881A (en) * | 1991-02-01 | 1991-09-10 | Swager William E | Lockable pin and clevis |
US5114260A (en) * | 1991-05-13 | 1992-05-19 | Hart Judy L | Clevis and screw pin type shackle with pin lock |
US5272824A (en) * | 1993-05-10 | 1993-12-28 | Caterpillar Inc. | Tooth assembly with leaf spring retainer |
US5423138A (en) * | 1994-04-04 | 1995-06-13 | Caterpillar, Inc. | Tip to adapter interface |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
CN1174741C (zh) * | 1999-09-21 | 2004-11-10 | Rtp药品公司 | 生物活性物质的表面改性微粒组合物 |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US20030166509A1 (en) * | 2001-11-20 | 2003-09-04 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery and methods of use thereof |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
BRPI0518187A (pt) * | 2004-11-16 | 2008-11-04 | Elan Pharma Int Ltd | formulações de olanzapina em nanopartìcula injetáveis |
TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
UA96436C2 (ru) * | 2006-01-20 | 2011-11-10 | Тиботек Фармасьютикелз Лтд. | Долгосрочное лечение вич-инфекции |
-
2007
- 2007-06-22 SI SI200732023T patent/SI2040671T1/en unknown
- 2007-06-22 WO PCT/EP2007/056230 patent/WO2007147882A2/en active Application Filing
- 2007-06-22 MX MX2009000158A patent/MX2009000158A/es active IP Right Grant
- 2007-06-22 DK DK07786802.4T patent/DK2040671T3/en active
- 2007-06-22 HU HUE07786802A patent/HUE038797T2/hu unknown
- 2007-06-22 ES ES07786802.4T patent/ES2662068T3/es active Active
- 2007-06-22 UY UY30431A patent/UY30431A1/es not_active Application Discontinuation
- 2007-06-22 AP AP2008004682A patent/AP2618A/xx active
- 2007-06-22 BR BR122020011487-8A patent/BR122020011487B1/pt active IP Right Grant
- 2007-06-22 CA CA2654115A patent/CA2654115C/en active Active
- 2007-06-22 PL PL07786802T patent/PL2040671T3/pl unknown
- 2007-06-22 PE PE2007000800A patent/PE20080210A1/es not_active Application Discontinuation
- 2007-06-22 BR BRPI0713334-0A patent/BRPI0713334B1/pt active IP Right Grant
- 2007-06-22 CL CL200701847A patent/CL2007001847A1/es unknown
- 2007-06-22 TW TW096122408A patent/TWI413521B/zh active
- 2007-06-22 SG SG2011045481A patent/SG173315A1/en unknown
- 2007-06-22 LT LTEP07786802.4T patent/LT2040671T/lt unknown
- 2007-06-22 EP EP18153008.0A patent/EP3366278A1/en active Pending
- 2007-06-22 UA UAA200813586A patent/UA97641C2/ru unknown
- 2007-06-22 NZ NZ573291A patent/NZ573291A/en unknown
- 2007-06-22 CN CN2007800236385A patent/CN101478950B/zh active Active
- 2007-06-22 AR ARP070102777A patent/AR061620A1/es not_active Application Discontinuation
- 2007-06-22 AU AU2007262941A patent/AU2007262941B2/en active Active
- 2007-06-22 KR KR1020097000969A patent/KR101406879B1/ko active IP Right Grant
- 2007-06-22 RS RS20180452A patent/RS57111B1/sr unknown
- 2007-06-22 JP JP2009515890A patent/JP5292288B2/ja active Active
- 2007-06-22 PT PT77868024T patent/PT2040671T/pt unknown
- 2007-06-22 US US12/305,276 patent/US20090176813A1/en not_active Abandoned
- 2007-06-22 EA EA200970047A patent/EA021700B1/ru unknown
- 2007-06-22 EP EP07786802.4A patent/EP2040671B1/en active Active
-
2008
- 2008-11-25 IL IL195491A patent/IL195491A/en active IP Right Grant
-
2014
- 2014-09-23 US US14/493,525 patent/US20150010637A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,297 patent/US11389447B2/en active Active
-
2018
- 2018-04-19 HR HRP20180629TT patent/HRP20180629T1/hr unknown
- 2018-04-24 CY CY20181100428T patent/CY1120564T1/el unknown
-
2020
- 2020-06-24 JO JOP/2020/0160A patent/JOP20200160A1/ar unknown
-
2022
- 2022-05-16 US US17/745,378 patent/US20220273653A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0713334A8 (pt) | suspensões aquosas de tmc278 | |
CL2011002878A1 (es) | Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih. | |
BR112013025987A2 (pt) | derivados de pirimidina para o tratamento de infecções virais | |
UA90124C2 (ru) | Способ профилактики вич-инфекции с помощью тмс278 | |
CL2004000930A1 (es) | Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos. | |
JO2755B1 (en) | (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection) | |
BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
CL2009002206A1 (es) | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. | |
BRPI0509140A (pt) | processos para o tratamento de infecção por hiv | |
SG170073A1 (en) | Long term treatment of hiv infection | |
EP4356968A3 (en) | Long-acting formulations | |
BRPI0920605A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. | |
BRPI1012666B8 (pt) | cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso | |
CR20110284A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
BR112023000220A2 (pt) | Formulações de longa ação | |
UY37488A (es) | Novedosas formulaciones de compuestos de beta-lactama sustituidos con amidina sobre la base de ciclodextrinas modificadas y agentes acidificantes, su preparación y uso como composiciones farmacéuticas antimicrobianas | |
CL2007001826A1 (es) | Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos. | |
EA201170004A1 (ru) | Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек | |
BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento | |
MX2012003424A (es) | Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana. | |
DK2044078T3 (da) | Camptothecinderivater med antitumoraktivitet | |
TH87271B (th) | สารผสมยา | |
CL2010001414A1 (es) | Compuestos derivados de diaminopiridina, pirimidina o piridazina, moduladores del receptor h4; composicion farmaceutica que lo comprende; y uso en el tratamiento de trastornos alergicos, dermatologicos, linfaticos, inmunodeficiencias, o enfermedades autoinmunes, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |